Skip to search formSkip to main contentSkip to account menu

Eloxatin

Known as: Eloxatine, Sanofi Synthelabo brand of oxaliplatin, Sanofi brand of oxaliplatin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The… 
2011
2011
Background and Objectives: To compare pathologic complete response (PCR) in patients with advanced rectal cancer receiving… 
2010
2010
Abstract Background. ECF (epirubicin, cisplatin, 5-FU) has been a standard first-line regimen in patients with advanced gastro… 
2006
2006
Cytotoxic activities of a test formulation (Oxitan ® ) were compared to a reference formulation (Eloxatin ® ) against a colon… 
2005
2005
Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman… 
2005
2005
Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N′] [oxalato(2-)-O,O′] platinum; Eloxatin) is a third-generation platinum… 
2003
2003
Neuropathy exacerbated by exposure to cold is a dose-limiting toxicity of oxaliplatin. The incidence of this side effect is… 
Review
2000
Review
2000
Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA… 
2000
2000
Many people are trying to be smarter every day. How's about you? There are many ways to evoke this case you can find knowledge… 
1998
1998
BACKGROUND/AIMS A retrospective report of our experience with adjuvant targeted locoregional immunochemotherapy using new drugs…